electroCore (ECOR) Competitors $5.66 -0.09 (-1.57%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$5.52 -0.14 (-2.39%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ECOR vs. LUCD, KRMD, PDEX, LUNG, ZJYL, OBIO, INFU, ICAD, MBOT, and GUTSShould you be buying electroCore stock or one of its competitors? The main competitors of electroCore include Lucid Diagnostics (LUCD), KORU Medical Systems (KRMD), Pro-Dex (PDEX), Pulmonx (LUNG), Jin Medical International (ZJYL), Orchestra BioMed (OBIO), InfuSystem (INFU), iCAD (ICAD), Microbot Medical (MBOT), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry. electroCore vs. Its Competitors Lucid Diagnostics KORU Medical Systems Pro-Dex Pulmonx Jin Medical International Orchestra BioMed InfuSystem iCAD Microbot Medical Fractyl Health Lucid Diagnostics (NASDAQ:LUCD) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability, community ranking and media sentiment. Do analysts rate LUCD or ECOR? Lucid Diagnostics currently has a consensus price target of $3.55, indicating a potential upside of 177.34%. electroCore has a consensus price target of $25.50, indicating a potential upside of 350.53%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than Lucid Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20electroCore 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, LUCD or ECOR? electroCore has higher revenue and earnings than Lucid Diagnostics. electroCore is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLucid Diagnostics$4.17M33.19-$52.67M-$1.34-0.96electroCore$26.46M1.59-$18.83M-$1.56-3.63 Do insiders and institutionals hold more shares of LUCD or ECOR? 74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 19.7% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is LUCD or ECOR more profitable? electroCore has a net margin of -54.40% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat electroCore's return on equity.Company Net Margins Return on Equity Return on Assets Lucid Diagnostics-1,069.87% N/A -123.54% electroCore -54.40%-154.45%-69.16% Does the media refer more to LUCD or ECOR? In the previous week, Lucid Diagnostics had 3 more articles in the media than electroCore. MarketBeat recorded 5 mentions for Lucid Diagnostics and 2 mentions for electroCore. Lucid Diagnostics' average media sentiment score of 1.11 beat electroCore's score of 0.43 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Overall Sentiment Lucid Diagnostics Positive electroCore Neutral Which has more volatility & risk, LUCD or ECOR? Lucid Diagnostics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, electroCore has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Does the MarketBeat Community prefer LUCD or ECOR? electroCore received 124 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. However, 69.35% of users gave Lucid Diagnostics an outperform vote while only 62.55% of users gave electroCore an outperform vote. CompanyUnderperformOutperformLucid DiagnosticsOutperform Votes4369.35% Underperform Votes1930.65% electroCoreOutperform Votes16762.55% Underperform Votes10037.45% SummaryLucid Diagnostics beats electroCore on 12 of the 19 factors compared between the two stocks. Get electroCore News Delivered to You Automatically Sign up to receive the latest news and ratings for ECOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ECOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ECOR vs. The Competition Export to ExcelMetricelectroCoreElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.00M$3.37B$5.57B$8.62BDividend YieldN/A1.75%5.28%4.18%P/E Ratio-3.0918.2627.1120.06Price / Sales1.59199.05409.88157.10Price / CashN/A44.0938.2534.64Price / Book4.563.917.064.70Net Income-$18.83M$94.03M$3.23B$247.88M7 Day Performance5.60%3.34%2.88%2.66%1 Month Performance17.43%11.80%9.04%6.40%1 Year Performance-13.06%22.02%31.40%14.07% electroCore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ECORelectroCore2.6015 of 5 stars$5.66-1.6%$25.50+350.5%-14.2%$42.00M$26.46M-3.0950LUCDLucid Diagnostics3.5387 of 5 stars$1.25-10.4%$3.50+181.1%+76.6%$134.70M$4.17M-1.0970Short Interest ↓Gap DownHigh Trading VolumeKRMDKORU Medical Systems3.6102 of 5 stars$2.79+3.3%$4.50+61.3%+39.1%$128.73M$35.08M-11.1680News CoveragePositive NewsPDEXPro-Dex3.1957 of 5 stars$39.24-2.0%$56.00+42.7%+110.3%$127.96M$64.12M19.52140News CoverageLUNGPulmonx3.6496 of 5 stars$3.13-7.9%$11.59+270.4%-49.4%$126.01M$87.47M-2.17250News CoverageGap DownZJYLJin Medical InternationalN/A$0.80+6.5%N/A-73.7%$125.24M$23.50M0.00245Short Interest ↓Gap DownOBIOOrchestra BioMed3.0686 of 5 stars$3.16+10.9%$14.20+349.4%-60.2%$121.07M$2.89M-1.964Positive NewsINFUInfuSystem2.2384 of 5 stars$5.68-1.7%$13.00+128.9%N/A$119.37M$137.58M94.68410Positive NewsShort Interest ↑ICADiCAD1.0477 of 5 stars$3.88+1.0%N/A+151.6%$106.59M$19.53M-29.85140Short Interest ↓MBOTMicrobot Medical1.9772 of 5 stars$2.67+5.1%$9.00+237.1%+133.6%$97.13MN/A-3.3420News CoverageOptions VolumeAnalyst RevisionGap DownGUTSFractyl Health2.0619 of 5 stars$1.90flat$11.00+478.9%-59.3%$93.06M$60K-0.16102Positive News Related Companies and Tools Related Companies LUCD Competitors KRMD Competitors PDEX Competitors LUNG Competitors ZJYL Competitors OBIO Competitors INFU Competitors ICAD Competitors MBOT Competitors GUTS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ECOR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding electroCore, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share electroCore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
